Drug Discovery for Kinetoplastid Diseases: Future Directions.


Journal

ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580

Informations de publication

Date de publication:
08 02 2019
Historique:
pubmed: 14 12 2018
medline: 18 12 2019
entrez: 14 12 2018
Statut: ppublish

Résumé

Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.

Identifiants

pubmed: 30543391
doi: 10.1021/acsinfecdis.8b00298
doi:

Substances chimiques

Antiprotozoal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-157

Subventions

Organisme : Medical Research Council
ID : MR/L018853/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S019650/1
Pays : United Kingdom

Auteurs

Srinivasa P S Rao (SPS)

Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.

Michael P Barrett (MP)

University of Glasgow , University Place , Glasgow G12 8TA , United Kingdom.

Glenn Dranoff (G)

Immuno-oncology , Novartis Institutes for Biomedical Research (NIBR) , 250 Massachusetts Avenue , Cambridge , Massachusetts 02139 , United States.

Christopher J Faraday (CJ)

Autoimmunity, Transplantation and Inflammation , NIBR , Fabrikstrasse 2 , CH-4056 Basel , Switzerland.

Claudio R Gimpelewicz (CR)

Global Drug Development, Novartis Pharma, Forum 1, CH-4056 Basel , Switzerland.

Asrat Hailu (A)

School of Medicine, Addis Ababa University , P.O. Box 28017 code 1000 , Addis Ababa , Ethiopia.

Catherine L Jones (CL)

Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.

John M Kelly (JM)

London School of Hygiene and Tropical Medicine , Keppel Street , London WC1E 7HT , United Kingdom.

Janis K Lazdins-Helds (JK)

Independent Consultant, Chemic Des Tulipiers 9 , 1208 Geneva , Switzerland.

Pascal Mäser (P)

Swiss Tropical and Public Health Institute, Socinstrasse 57, 4501 Basel, Switzerland; University of Basel , CH 4000 Basel , Switzerland.

Jose Mengel (J)

Laboratory of Clinical Immunology , Oswaldo Cruz Institute , FIOCRUZ-RJ, Av. Brasil 4365 , Cep: 21040-900 , Rio de Janeiro -RJ, Brazil.
Faculty of Medicine of Petropolis , University in Petròpolis , Av. Barao do Rio Branco 1003 , Cep: 25680-120 , Petropolis -RJ, Brazil.

Jeremy C Mottram (JC)

University of York , Wentworth Way Heslington , York YO10 5DD , United Kingdom.

Charles E Mowbray (CE)

Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant , 1202 Geneva , Switzerland.

David L Sacks (DL)

National Institute of Allergy and Infectious Diseases , 4 Memorial Drive , Bethesda , Maryland 20892 , United States.

Phillip Scott (P)

University of Pennsylvania , 380 South University Avenue , Philadelphia , Pennsylvania 19104 , United States.

Gerald F Späth (GF)

Institut Pasteur, 25 Rue du Docteur Roux , 75015 Paris , France.

Rick L Tarleton (RL)

University of Georgia , Coverdell Center, 500 DW Brooks Dr , Athens , Georgia 30602 , United States.

Jonathan M Spector (JM)

Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.

Thierry T Diagana (TT)

Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH